Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2143-2150
Published online before print July 7, 2005, doi: 10.1161/01.ATV.0000176971.27302.b0
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/10/2143    most recent
01.ATV.0000176971.27302.b0v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ross, C. J.D.
Right arrow Articles by Hayden, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, C. J.D.
Right arrow Articles by Hayden, M. R.
Related Collections
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2143.)
© 2005 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Complete Rescue of Lipoprotein Lipase–Deficient Mice by Somatic Gene Transfer of the Naturally Occurring LPLS447X Beneficial Mutation

Colin J.D. Ross; Guoqing Liu; Jan Albert Kuivenhoven; Jaap Twisk; Jaap Rip; Willemijn van Dop; Katherine J.D. Ashbourne Excoffon; Suzanne M.E. Lewis; John J. Kastelein; Michael R. Hayden

From the Department of Medical Genetics (C.J.D.R., G.L., K.J.D.A.E., S.M.E.L., M.R.H.), University of British Columbia, Centre for Molecular Medicine and Therapeutics, Vancouver, Canada; the Department of Experimental Vascular Medicine (J.A.K., J.R., W.v.D., J.J.K.), University of Amsterdam, Academic Medical Center, the Netherlands; Amsterdam Molecular Therapeutics (J.T.), the Netherlands.

Correspondence to Michael R. Hayden, Centre for Molecular Medicine and Therapeutics, 950 West 28th Ave, Vancouver, BC, Canada V5Z-4H4. E-mail mrh{at}cmmt.ubc.ca

The naturally occurring human lipoprotein lipase S447X variant (LPLS447X) exemplifies a gain-of function mutation with significant benefits including decreased plasma triglycerides (TG), increased high-density lipoprotein (HDL) cholesterol, and reduced risk of coronary artery disease. The S447X variant may be associated with higher LPL catalytic activity; however, in vitro data supporting this hypothesis are contradictory. We wanted to investigate the in vivo mechanism by which the LPLS447X variant improves the lipid profile of S447X carriers. We conducted a functional assessment of human LPLS447X compared with LPLWT in mice. LPL variants were compared in the absence of endogenous mouse LPL in newborn LPL–/– mice by adenoviral-mediated gene transfer. LPL–/– mice normally exhibit severe hypertriglyceridemia and die within 48 hours of birth. LPLWT gene transfer prolonged the survival of mice up to 21 days. In contrast, LPLS447X completely rescued 95% of the mice to adulthood and increased LPL catalytic activity in postheparin plasma 2.1-fold compared with LPLWT at day 3 (P=0.003). LPLS447X also reduced plasma TG 99% from baseline (P<0.001), 2-fold more than LPLWT, (P<0.01) and increased plasma HDL cholesterol 2.9-fold higher than LPLWT (P<0.01). These data provide in vivo evidence that the increased catalytic activity of LPLS447X improves plasma TG clearance and increases the HDL cholesterol pool compared with LPLWT.

We investigated the in vivo mechanism by which naturally occurring LPLS447X variant improves the lipid profile of S447X carriers by comparing human LPLS447X to LPLWT in newborn LPL–/– mice. LPLWT prolonged newborn survival to 21 days. In contrast, the increased catalytic activity of LPLS447X completely rescued LPL–/– mice to adulthood.


Key Words: beneficial mutation • chylomicronemia • lipoprotein lipase • type 1 hyperlipoproteinemia


Related Article:

Gain-of-Function Mutations and Therapeutic Implications: Lipoprotein Lipase S447X to the Rescue
Daniel J. Rader
Arterioscler Thromb Vasc Biol 2005 25: 2018-2019. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Neurosci.Home page
X. Xian, T. Liu, J. Yu, Y. Wang, Y. Miao, J. Zhang, Y. Yu, C. Ross, J. M. Karasinska, M. R. Hayden, et al.
Presynaptic Defects Underlying Impaired Learning and Memory Function in Lipoprotein Lipase-Deficient Mice
J. Neurosci., April 8, 2009; 29(14): 4681 - 4685.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
Y Wang, L Sternfeld, F Yang, J A Rodriguez, C Ross, M R Hayden, F Carriere, G Liu, W Hofer, and I Schulz
Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipase-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells
Gut, March 1, 2009; 58(3): 422 - 430.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
X. Zhang, R. Qi, X. Xian, F. Yang, M. Blackstein, X. Deng, J. Fan, C. Ross, J. Karasinska, M. R. Hayden, et al.
Spontaneous Atherosclerosis in Aged Lipoprotein Lipase-Deficient Mice With Severe Hypertriglyceridemia on a Normal Chow Diet
Circ. Res., February 1, 2008; 102(2): 250 - 256.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
G. Yuan, K. Z. Al-Shali, and R. A. Hegele
Hypertriglyceridemia: its etiology, effects and treatment
Can. Med. Assoc. J., April 10, 2007; 176(8): 1113 - 1120.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Wang, X. Xian, W. Huang, L. Chen, L. Wu, Y. Zhu, J. Fan, C. Ross, M. R. Hayden, and G. Liu
Expression of LPL in Endothelial-Intact Artery Results in Lipid Deposition and Vascular Cell Adhesion Molecule-1 Upregulation in Both LPL and ApoE-Deficient Mice
Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 197 - 203.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Rip, M. C. Nierman, C. J. Ross, J. W. Jukema, M. R. Hayden, J. J.P. Kastelein, E. S.G. Stroes, and J. A. Kuivenhoven
Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation
Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1236 - 1245.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. A. Hegele, C. J.D. Ross, J. Twisk, J. A. Kuivenhoven, J. Rip, J. J. Kastelein, and M. R. Hayden
Gene therapy with lipoprotein lipase variant S447X.
Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): e25 - e25.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. J. Rader
Gain-of-Function Mutations and Therapeutic Implications: Lipoprotein Lipase S447X to the Rescue
Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2018 - 2019.
[Full Text] [PDF]